|
1) Finn OJ. Cancer immunology. N Engl J Med. 2008; 358: 2704-15
|
|
|
|
2) Rosenberg SA, Restifo NP, Yang JC, et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer. 2008; 8: 299-308
|
|
|
|
|
|
3) Rosenberg SA, Yannelli JR, Yang JC, et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst. 1994; 86: 1159-66
|
|
|
|
|
|
4) Figlin RA, Thompson JA, Bukowski RM, et al. Multicenter, randomized, phase III trial of CD8(＋) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J Clin Oncol. 1999; 17: 2521-9
|
|
|
|
|
|
5) Dreno B, Nguyen JM, Khammari A, et al. Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma. Cancer Immunol Immunother. 2002; 51: 539-46
|
|
|
|
|
|
6) Kono K, Takahashi A, Ichihara F, et al. Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer: a randomized trial. Clin Cancer Res. 2002; 8: 1767-71
|
|
|
|
|
|
7) Yee C, Thompson JA, Byrd D, et al. Adoptive T cell therapy using antigen-specific CD8＋ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A. 2002; 99: 16168-73
|
|
|
|
|
|
8) Dudley ME, Wunderlich J, Nishimura MI, et al. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother (1997). 2001; 24: 363-73
|
|
|
|
|
|
9) Dudley ME, Wunderlich JR, Yang JC, et al. A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother (1997). 2002; 25: 243-51
|
|
|
|
|
|
10) Mitchell MS, Darrah D, Yeung D, et al. Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope. J Clin Oncol. 2002; 20: 1075-86
|
|
|
|
|
|
11) Heslop HE, Ng CY, Li C, et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med. 1996; 2: 551-5
|
|
|
|
|
|
12) Dudley ME, Wunderlich JR, Shelton TE, et al. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother. 2003; 26: 332-42
|
|
|
|
|
|
13) Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005; 23: 2346-57
|
|
|
|
|
|
14) Huang J, Khong HT, Dudley ME, et al. Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression. J Immunother. 2005; 28: 258-67
|
|
|
|
|
|
15) Powell DJ Jr, Dudley ME, Robbins PF, et al. Transition of late-stage effector T cells to CD27＋ CD28＋ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood. 2005; 105: 241-50
|
|
|
|
|
|
16) Shen X, Zhou J, Hathcock KS, et al. Persistence of tumor infiltrating lymphocytes in adoptive immunotherapy correlates with telomere length. J Immunother. 2007; 30: 123-9
|
|
|
|
|
|
17) Heemskerk B, Liu K, Dudley ME, et al. Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2. Hum Gene Ther. 2008; 19: 496-510
|
|
|
|
|
|
18) Vignard V, Lemercier B, Lim A, et al. Adoptive transfer of tumor-reactive Melan-A-specific CTL clones in melanoma patients is followed by increased frequencies of additional Melan-A-specific T cells. J Immunol. 2005; 175: 4797-805
|
|
|
|
|
|
19) Hunder NN, Wallen H, Cao J, et al. Treatment of metastatic melanoma with autologous CD4＋ T cells against NY-ESO-1. N Engl J Med. 2008; 358: 2698-703
|
|
|
|
|
|
20) Mackensen A, Meidenbauer N, Vogl S, et al. Phase I study of adoptive T-cell therapy using antigen-specific CD8＋ T cells for the treatment of patients with metastatic melanoma. J Clin Oncol. 2006; 24: 5060-9
|
|
|
|
|
|
21) Powell DJ Jr, Dudley ME, Hogan KA, et al. Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion. J Immunol. 2006; 177: 6527-39
|
|
|
|
|
|
22) Gottschalk S, Rooney CM, Heslop HE. Post-transplant lymphoproliferative disorders. Annu Rev Med. 2005; 56: 29-44
|
|
|
|
|
|
23) Bollard CM, Aguilar L, Straathof KC, et al. Cytotoxic T lymphocyte therapy for Epstein-Barr virus＋ Hodgkin's disease. J Exp Med. 2004; 200: 1623-33
|
|
|
|
|
|
24) Straathof KC, Bollard CM, Popat U, et al. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood. 2005; 105: 1898-904
|
|
|
|
|
|
25) Bollard CM, Gottschalk S, Leen AM, et al. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood. 2007; 110: 2838-45
|
|
|
|
|
|
26) Hirano N, Butler MO, Xia Z, et al. Engagement of CD83 ligand induces prolonged expansion of CD8＋ T cells and preferential enrichment for antigen specificity. Blood. 2006; 107: 1528-36
|
|
|
|
|
|
27) Butler MO, Lee JS, Ansen S, et al. Long-lived antitumor CD8＋ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell. Clin Cancer Res. 2007; 13: 1857-67
|
|
|
|
|
|
28) Stauss HJ, Cesco-Gaspere M, Thomas S, et al. Monoclonal T-cell receptors: new reagents for cancer therapy. Mol Ther. 2007; 15: 1744-50
|
|
|
|
|
|
29) Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006; 314: 126-9
|
|
|
|
|
|
30) Rossig C, Brenner MK. Genetic modification of T lymphocytes for adoptive immunotherapy. Mol Ther. 2004; 10: 5-18
|
|
|
|
|
|
31) Lamers CH, Sleijfer S, Vulto AG, et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol. 2006; 24: e20-2
|
|
|
|
|
|
32) Kershaw MH, Westwood JA, Parker LL, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res. 2006; 12: 6106-15
|
|
|
|
|
|
33) Park JR, Digiusto DL, Slovak M, et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther. 2007; 15: 825-33
|
|
|
|
|
|
34) Till BG, Jensen MC, Wang J, et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood. 2008; 112: 2261-71
|
|
|
|
|